Vimta Labs share price today

Vimta Labs Ltd's share price was ₹497.85 at the close on 4 November 2026. It has been rising for 16 weeks. That is 10.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹401 and ₹658, and at that close it sat 38% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Vimta Labs Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running.

Over the last 11 years the share price moved +1,317% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: promoters cut their stake for 8 quarters in a row, revenue up on a year earlier for 9 quarters in a row and indian funds and insurers (DIIs) raised their stake for 3 quarters in a row.

1. Promoters cut their stake for 8 quarters in a row

   From 36.9% to 35.6% of the company by the September 2026 quarter.

2. Revenue up on a year earlier for 9 quarters in a row

   In the September 2026 quarter revenue was ₹112 crore, +9.8% on a year earlier.

   Why: Revenue rose because preclinical testing demand was strong and long-term analytical client work stayed steady.

   Next results: check whether clinical and food testing volumes improve in the stronger second half.

   From the earnings call on 30 Oct 2026.

3. Indian funds and insurers (DIIs) raised their stake for 3 quarters in a row

   From 0.1% to 0.5% of the company by the September 2026 quarter.

For July to September 2026 (the quarter ended 30 September 2026), Vimta Labs reported revenue of ₹112 crore, up 9.8% from ₹102 crore a year earlier, and a profit of ₹21.0 crore, up 5.0% from ₹20.0 crore.

Vimta Labs results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Vimta Labs' management discussed these results on a call held on 30 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Vimta Labs closed at ₹497.85 on 4 November 2026, down 24.3% from ₹657.80 a year earlier (7 November 2025) and up 174.4% over five years. Its highest weekly close since March 2016 was ₹877.20 on 5 September 2025.

Vimta Labs share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Vimta Labs closed at ₹497.85, up 2.7% on the week and down 14.7% on the month. 30 Oct 2026: Vimta Labs held its results call for July to September 2026. Management guided: FY28 revenue around ₹700 crore implying around 20-25% yearly growth with operating profit 35-36%.

Earlier

• Results for July to September 2026: Revenue up 9.8% and profit up 5.0% on a year earlier.
• 18 Jun 2026: ex-date for a dividend of ₹2 a share.
• 13 Jun 2025: Bonus issue: 1 new share for every 1 held (ex-date).

Vimta Labs paid ₹2 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.40% at the ₹497.85 close on 4 November 2026. The last was a dividend of ₹2 a share, ex-date 18 June 2026.

Vimta Labs dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Vimta Labs Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 10 of its last 12 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 30 October 2026, Vimta Labs' management guided: FY28 revenue around ₹700 crore implying around 20-25% yearly growth with operating profit 35-36%.

“A key milestone during Q2 was the commencement of revenue generation from our biologics services.”Harita Vasireddi, on the call for July to September 2026

What management guided

• FY27 capital spending around ₹80 crore including maintenance ₹45-50 crore with H2 catch-up spread across analytical, preclinical, food and molecule work.
• Near-term margins broadly stable with medium-term 100-200 basis points moderation on biologics mix.
• Q3-Q4 improvement in large-molecule CRDS, clinical and food volumes on pipeline conversion.
• Biologics couple onboardings this quarter with 1:1 return goal by third year, possibly second.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 30 October 2026.

When Vimta Labs reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Food sample flows returning to earlier volumes on export-import recovery - check flagged normalisation timeline.

Vimta Labs is not on any of our India lists this week.

Vimta Labs Ltd earned ₹21.0 Cr of net profit in the Sep 2026 quarter, +5.0% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹78.0 Cr. Over 10 years profit has grown 29.2% a year on average. That is 18.8% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹20.0 Cr.

For the full year, FY26 profit was ₹78.0 Cr (+16.4% on the year before).

Why profit moved: revenue changed +9.8% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +3.5% and revenue +11.8%. Profit is growing slower than sales: rising costs are taking part of the growth.

Vimta Labs Ltd reported ₹112 Cr of revenue in the Sep 2026 quarter, +9.8% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 10 years it has grown 11.4% a year on average. The last full year, FY26, came in at ₹407 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹429 Cr.

FY26 revenue was ₹407 Cr, +18.3% on the year before.

Recent pace: the last four quarters grew +11.8% on average, against 11.4% a year over the longer run, so this year is growing at about the same pace as its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +11.7%, against +18.4% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +2.5%, against +29.9% a year (rolling over).

Vimta Labs Ltd's operating margin was 34.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 12 years it has been between 14.0% and 35.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.2 percentage points on the year while gross margin changed −3.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 162% of Vimta Labs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹147 Cr of operating cash against ₹78.0 Cr of profit. After ₹99.0 Cr of spending on assets, ₹48.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 162% of profit came in as cash: the cash cycle got 91 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 2.3× depreciation over three years. The next section checks what that spending is building.

Vimta Labs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 219 days in FY26, up from 128 days in FY21. It spent ₹255 Cr on assets over the last 3 years. Customers take 95 days to pay, and stock sits for 203 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹407 Cr, each day of that cycle ties up about ₹1.1 Cr, so roughly ₹244 Cr is tied up in the business at any time.

FY26: customers took 95 days to pay and stock sat for 203 days, about 6.7 months of sales sitting as stock, for a full cycle of 219 days, longer than FY21's 128.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 203 days. Customers pay about 95 days after that. Suppliers are paid at 79 days. Together that makes the 219-day cycle.

Spending on assets: ₹255 Cr over the last 3 years, against ₹112 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹18.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Vimta Labs Ltd's P/E is 27.3×, in the middle of its own history: higher than 58% of past readings. Its usual P/E (the middle reading) is 26.2×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹17.99.